Overview on the Recent Drugs Delivery Approaches by Amly, Wajd & Karaman, Rafik
See	discussions,	stats,	and	author	profiles	for	this	publication	at:	https://www.researchgate.net/publication/292960590
Overview	on	the	Recent	Drugs	Delivery
Approaches
Article	·	February	2016
DOI:	10.14437/2378-8968-2-114
CITATION
1
READS
254
2	authors:
Wajd	Amly
Al-Quds	University
6	PUBLICATIONS			40	CITATIONS			
SEE	PROFILE
Rafik	Karaman
Al-Quds	University
233	PUBLICATIONS			2,820	CITATIONS			
SEE	PROFILE
Available	from:	Rafik	Karaman
Retrieved	on:	04	September	2016
 
 
Volume 2 • Issue 1 • 114                                       www.aperito.org 
 
 
 
 
Aperito Journal of Pharmacology 
and Drug Design 
          Received: Nov 22, 2015 
         Accepted: Jan 29, 2016 
         Published: Feb 01, 2016 
 
 
 
Overview on the Recent Drugs Delivery Approaches 
Wajd Amly1 and Rafik Karaman1,2* 
1Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem, Palestine  
2Department of Sciences, University of Basilicata, Viadell’Ateneo Lucano 10, 85100, Potenza, Italy 
Abstract  
This review provides the reader a concise overview of 
the different biological barriers that hinder the delivery of 
therapeutic agents through membranes, such as intestinal mucosa, 
Brain Blood Barrier (BBB), and mediators of transport such as 
efflux transporters and etc., and the approaches for overcoming 
such barriers. The approaches discussed in this review include: 
utilizing natural occurring transporters to deliver drugs 
specifically to their targets, nucleoside analogues delivery, CYP-
activated prodrugs that target drugs to the liver, modification of 
passive diffusion by efflux pumps, intestinal transporters such as 
PEPT1 and GLUT1, Carrier Mediated Transport (CMT) systems 
for transporting nutrients, vitamins or hormones into the central 
nervous system, tissue selective drug delivery, administration of 
an exogenous enzyme to reach the tumor site which is followed 
by systemic administration of non-toxic prodrugs (ADEPT, 
GDEPT and VDEPT),  enzymes involve in the bioconversion of 
ester-based prodrugs for activation (hydrolysis) of prodrugs to 
their active forms, brain targeted Chemical Delivery Systems 
(CDS), amino acid prodrugs to improve oral bioavailability, 
sustained drug delivery and intravenous drug delivery.  
In addition, Receptor-Mediated Transcytosis (RMT) for 
efficacious delivery of Nano particles through the intestinal 
mucosa and BBB, and the prodrug chemical approach based on 
intra molecularity to deliver anti-cancer drugs is discussed.  
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Introduction 
The presence of barriers such as intestinal mucosa and 
Blood Brain Barrier (BBB) is considered one of the major 
concerns when developing a drug since they pose a hurdle to the 
delivery of drugs to their active sites (targets). Strategies to 
overcome such barriers include altering the drug’s 
physicochemical properties aiming to improve its absorption. 
Other strategies involve improving drug’s transcellular delivery 
by blocking the efflux pumps or enhancing its paracellular 
transport via modulation of cell–cell adhesion in the intercellular 
junctions [1].  
During the last two decades, many approaches and 
methods have been developed for facilitating the drug design and 
discovery phases. The majority of these methods were 
concentrated in finding new chemical entities that provide the 
most meaningful interaction with the desired receptors or 
enzymes and potentially to have minimal undesired interactions. 
However, this strategy is time consuming, costly and requires 
screening of thousands of molecules for biological activity of 
which a single compound might enter the drug market. One of the 
most attractive and promising method is the prodrug approach, in 
which the active drug molecule is masked by a promoiety to alter 
its undesired properties. The prodrug (predrug, proagent) is 
defined as a pharmacologically inactive moiety which is 
converted to an active form within the body. This term has been 
successfully used to alter the physicochemical, pharmacokinetic 
properties, (absorption, distribution, excretion and metabolism) of 
drugs and to decrease their associated toxicity. A prodrug must 
undergo chemical and/or enzymatic biotransformation in a 
controlled or predictable manner prior to exert its therapeutic 
activity. Basically, the use of the term prodrug implies a covalent 
link between an active drug and a promoiety. This strategy is
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designed to overcome barriers through a chemical approach rather 
than a formulation approach [2, 3]. 
A schematic diagram shown in Figure 1 illustrates the 
intestinal mucosa barrier (Figure 1A) and brain blood barrier 
(BBB) (Figure 1B) that drugs generally penetrate through cell 
membranes (transcellular pathway) or in between the cells 
(paracellular pathway) [1, 4].  
Figure 1: A schematic diagram illustrating the intestinal mucosa 
barrier and BBB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical & metabolic barriers characteristics 
The intestinal mucosa and BBB impose physical barriers 
that preclude the drug from reaching its site of action. As for 
BBB, the Brain Capillary Endothelial Cells (BCECs) are the most 
fundamental physical structure that composes this barrier. The 
BBB possesses some exceptional characteristics such as the 
existence of tight junctions, high metabolic activity of cells, 
inadequate vesicular transport (endocytosis) and an absence of 
fenestrations which in turn prohibit paracellular transport of the 
solute molecules [5].  
Moreover, biochemical barriers such as enzymes and 
efflux pumps such as Multidrug-Resistant Proteins (MRP) and P-
glycoproteins (P-gp), and many others ATP-dependent pumps 
have the potential to prohibit drug molecules from passing 
through biological barriers. Thus, it is expected that the 
determination of the substrate structural recognition will be quite 
difficult [1]. 
Enhancing the delivery of drug via transcellular pathways 
Enhancing the passive diffusion of drugs through the 
transcellular pathway is a method to improve drug delivery 
through BBB and intestinal mucosa. The concept for passing 
transcellularly through the intestinal mucosa is partitioning of the 
drug molecules between two morphologically and functionally 
different cell membranes. Drugs molecules cross into the apical 
side, entering the intracellular space by influence of concentration 
gradient which is followed by molecules partitioning into the cell 
membranes at the basolateral side and from there they enter the 
systemic circulation [1, 6]  
Drugs intended to enter the Central Nervous System 
(CNS) have to pass the BBB; the BBB contains tight-junctions 
which only permit the transport of lipophilic compounds to 
traverse it by diffusion or if the compound is a substrate for DBB 
carrier mediated transporters, also transcytosis takes place which 
can be absorptive mediated or receptor mediated trans cytosis [2]. 
 Changing the drugs’ physicochemical properties 
(transiently) in a way that favors membrane partitioning is among 
the methods used to improve the passive diffusion of drugs via 
transcellular pathway [7]. This can be achieved by developing a 
prodrug with a  labile promoiety, that cleaved after passing 
biological barriers [8]. Drug’s molecular size, charge, 
lipophilicity, hydrogen-bonding capability and solubility are the 
main factors determining the drug’s permeation and its transport 
properties [7, 9]. However, in the case of peptides and proteins, 
the conformation and dynamic properties are important factors to 
be considered [1].  
Nucleosides and approaches applied for drug delivery 
Nucleoside analogues are entities consisting of a nucleic acid 
analogue and a sugar. They are commonly and widely used to 
treat viral infections and tumors. However, many nucleoside 
analogues have poor oral bioavailability due to their high polarity 
and low absorption through membranes (low permeability).  
The poor absorption of many of nucleoside analogues is 
attributed to the large difference between the permeation of 
natural nucleosides and nucleoside analogues into cell 
membranes. Generally, natural nucleosides permeate cell 
membranes via active transport using Na+-dependent 
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concentrative- and Na+-independent equilibrated- transporters due 
to their significant hydrophilicity, whereas a passive diffusion or 
a combination of passive diffusion and nucleoside transporters is 
the pathway of the nucleoside analogues penetration into cells [4, 
10]. Furthermore, it has been proposed that synthetic nucleoside 
analogues are not good substrates of nucleoside transporters, and 
since the capacity of these transporters is low, their saturation is 
reached at typical intestinal drug concentrations, the permeation 
of the synthetic nucleosides into cell membranes is therefore 
limited [4, 11].  
Various chemical approaches have been applied to 
increase the nucleoside analogues lipophilicity and hence to 
enhance their oral absorption. Among these approaches: 
esterification, amidation, carbamation and synthesis of Prodrugs 
of Acyclic (ANP) and Cyclic (CNP) Nucleoside Phosphonates. In 
the ANP and CNP prodrugs the negative charges on the 
phosphonate groups are substituted with an alkyl group which 
results in enhancing the drug’s permeation [4].  
Prodrugs of Acyclic (ANP) and Cyclic Nucleoside 
Phosphonates (CNP) 
Significant efforts have been made in the development 
of phosphonate-containing drugs for application in the treatment 
of various diseases. However, the free diacid phosphonates are 
ionized at physiological pH resulting in the formation of the 
corresponding dianion phosphonate drugs which have very poor 
oral bioavailability. To overcome this disadvantage a number of 
prodrugs for active phosphonate analogues have been developed. 
The concept of designing such prodrugs was to mask the free 
phosphonic group of the parent drug until being absorbed and 
reached the drug’s target then the prodrug is allowed to undergo 
cleavage to release the active drug.  
ANP and CNP analogues are converted into diphosphate 
analogues and inhibit viral DNA polymerase. Uniquely, ANP and 
CNP analogues do not rely on viral nucleoside kinases to initiate 
phosphorylation; they can employ their antiviral effect due to 
being monophosphorylated compounds. However, ANP and CNP 
analogues re converted to their active forms by the action of 
cellular enzymes that activate two phosphorylation processes. 
Thus, ANP and CNP analogues reduce the prevalence of virus 
drug resistance [4, 12, 13].  
Several acyloxy ester and alkoxycarbonyl ester prodrugs 
of ANP analogues have been developed and among these, two 
prodrugs are currently in the market for the treatment of viral 
infections: the bis (pivaloyloxymethyl) ester of adefovir (1 in 
Figure 2, bis-(POM)-PMEA; Hepsera®), approved in 2002 for 
the treatment of HBV infections and the 
diisopropyloxycarbonyloxymethyl ester of tenofovir fumarate (2 
in Figure 2, bis-(POC)-(R)-PMPA fumarate; Viread®) which was 
approved in 2001 for the treatment of HIV infections, and in 2008 
for the treatment of chronic HBV. 
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A bis(pivaloyloxymethyl) ester prodrug of adefovir, 1, 
was designed and developed due to its favorable physicochemical 
properties. The prodrug showed enhanced lipophilicity and 
increased intestinal permeability compared to its active parent 
drug, adefovir (3 in Figure 2). In addition, it demonstrated a rapid 
transformation to adefovir in vivo, which resulted in a significant 
increase in the oral bioavailability of the drug. Moreover, results 
demonstrated that the permeability of adefovir dipivoxil, 1, in 
Caco-2 cell monolayers was 7.9×10-6 cm/s whereas that of 
adefovir was 1.0×10-6 cm/s. This increased permeability for 1 
resulted in bioavailability of 36– 45% for 125–500 mg doses 
compared to less than 12% for adefovir, 3 [4, 14]. 
Prodrug 2 is a modification of 1 which offers the 
advantage of not generating pivalic acid during its bioconversion; 
1 was found to be toxic during long-term use due to its 
decomposition products, formaldehyde and pivalic acid. The bis-
(POC) motif was applied for the synthesis of bis-(POC)-(R)-
PMPA, 2, which was selected for clinical trials and was approved 
in the form of fumarate salt to treat of HIV. In addition, Bis-
(POC)-(R)-PMPA fumarate, 2, is currently in the market for use 
in combination with emtricitabine (Truvada®), and emtricitabine 
and efavirenz (Atripla®). 
Subsequently, PMCDG dipivoxil (4, bis-(POM)-
PMCDG in Figure 3) was synthesized to be used orally for HBV 
treatment and it is now in clinical trials. The prodrug 4 undergoes 
rapid esterase catalyzed-hydrolysis to its parent drug, PMCDG, in 
the liver and intestine. PMCDG is then degraded to a nucleotide 
analogue of guanosine monophosphate 5, by aldehyde or xanthine 
oxidase (Figure 3). After phosphorylation to di- and triphosphate 
forms, the resulting entity inhibits viral replication upon 
incorporation into viral DNA ([4, 14]). 
Figure 3: Metabolic pathway of prodrug 4 to 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prodrugs of Cyclic Peptides 
Peptide drugs are associated with difficulty crossing the 
intestinal mucosa and BBB owing to their physicochemical 
properties that do not favor permeation into cell membranes via 
transcellular transport. They also restricted from crossing via 
paracellular route because of their large size which inhibits their 
passage through the tight junctions in this route.  
To overcome this obstacle cyclic peptide prodrugs have 
been developed (Figure 4). The strategy was to modify the 
peptides’ physicochemical properties such that it allows their 
permeation via transcellular passive diffusion. In contrast to the 
parent linear peptides, the cyclic peptide prodrugs showed less 
hydrogen-bonding capability, greater partition coefficients and 
reduced hydrodynamic radii. Yet, alongside the advantages, there 
are still some drawbacks associated with the cyclic peptide 
prodrugs. These disadvantages include recognition enhancement 
by efflux pumps and metabolism by cytochrome P450 (CP450), 
chemical instability of the cyclic promoiety in formulations and 
the risk of inter conversion of the cyclic prodrug to its acyclic 
active parent drug by enzymes before and during the diffusion 
across cellular barriers. This can lead to trapping of the drug 
inside the cells of the barrier and thus inhibiting the drug from 
crossing through the barrier [1].  
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Figure 4: A schematic diagram showing the conversion of the cyclic acyloxy alkoxy peptide prodrug to its parent peptide by esterase 
enzymes (slow reaction, few hours) followed by a fast chemical reaction (instantly, within few minutes). 
 
 
 
 
 
 
 
 
 
 
 
 
 
HepDirect Prodrugs 
HepDirect prodrugs symbolize a novel class of CYP-activated prodrugs that target drugs to the liver. In this class, the drug is 
chemically modified to form a cyclic 1,3-propanyl ester prodrug of phosphonate or phosphate, which is pharmacologically inactive until it 
reaches the liver where it undergoes enzyme-catalyzed cleavage to release the active drug. In addition, HepDirect prodrugs are stable in the 
blood circulation and most of the body tissues except the liver owing to their resistant to cleavage by esterases. 
As mentioned earlier, adefovir dipivoxil prodrug was developed to enhance the low oral bioavailability of adefovir; however, the 
prodrug exhibited dose-limiting nephrotoxicity. For this reason, pradefovir, a HepDirect prodrug of adefovir, 6, was designed and developed. 
Studies demonstrate that upon reaching the liver, pradefovir 6, is hydroxylated by CYP3A4 isozyme at the C4-methine position, followed by 
a rapid ring opening and β-elimination reaction to yield adefovir, 7, and aryl vinyl ketone (Figure 5). [4, 15]. 
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Subsequently, adefovir is transformed by nucleotide 
kinases to adefovir diphosphate, whereas the aryl vinyl ketone 
forms a glutathione conjugate. In addition, studies revealed that in 
contrast to adefovir dipivoxil prodrug, pradefovir prodrug has 
good liver targeting properties and low risk of nephrotoxicity [4, 
16, 17].  
Modification of passive diffusion by efflux pumps or 
intracellular sequestration 
Efflux pumps 
As previously mentioned, existence of efflux pumps 
contributes to poor delivery of drugs through the intestinal 
mucosa and BBB. The proposed explanation for this phenomenon 
is that these pumps have the ability to distinguish and identify 
molecules with hydrophobic aromatic and/or tertiary amino 
groups and thus inhibit their permeation.  
Using the X-ray structure of P-gp, various mechanisms of action 
of efflux pumps were proposed such as pore generation, 
hydrophobic vacuum cleaner and flippase mechanisms. Based on 
these proposals different methods were suggested and developed 
to avoid the activity of P-gp. Among these methods: drugs 
adjustment to prevent P-gp recognition, drugs with the potential 
to competitively inhibit P-gp and inhibitors that cause failure to 
P-gp function or completely shut it [1, 18].  
The broadly known agents that have been recognized as 
competitive inhibitors of P-gp are verapamil, Cyclosporine A 
(CsA) and LY335979. Moreover, cyclosporine D (SDZ PCS833) 
has been used to improve intestinal mucosa delivery of some 
drugs due to its potential to inhibit P-gp without 
immunosuppressive activity that is associated with CsA. A 
number of pharmaceutical excipients such as surfactants (i.e., 
polysorbate 80, cremophore) and polymers (i.e., polyethylene 
glycols) have also been associated with P-gp inhibition and thus, 
drug transport enhancement [1, 19]. 
Another technique that has been explored to inhibit P-gp 
and enhance drug delivery to the brain is dimer prodrug 
formation. This technique is based on the assumption that the 
ability of the dimer to occupy multiple binding sites on P-gp can 
been reached via blocking P-gp activity which concurrently 
enhances prodrug transport through the BBB. Examples for such 
technique are galantamine dimer, Gal-2 (Figure 6) and abcavir 
dimer, NBD-abcavir (Figure 7) prodrugs that have demonstrated 
higher binding affinities and lower the off-rate to P-gp receptors 
compared to their corresponding parent monomers, galantamine 
and abcavir monomers, respectively (Figures 6 and 7). NBD-
abcavir was assembled by connecting two abcavir molecules with 
a disulfide bond promoiety and its uptake in rat brain micro vessel 
endothelial cells was shown to be greater than abcavir due to its 
success in inhibiting P-gp. Abcavir is released from the NBD-
abcavir prodrug after disulfide cleavage which is followed by a 
promoiety cyclization [1, 20]. On the other hand, Gal-2 dimer has 
been shown to convert to galantamine monomer by esterase 
enzyme. 
In addition, the codrug approach has been utilized to 
enhance drug delivery to the Central Nervous System (CNS) by 
chemically attaching a drug with efflux inhibitor such as P-gp 
inhibitor. For instance, entacapone; the catechol-O-
methyltransferase inhibitor was coupled with L-dopa to increase 
the delivery of the latter into the brain. Despite its success, the 
codrug approach is not the optimal choice to treat chronic CNS 
diseases because of toxic metabolites that might be accumulated 
in the CNS if the efflux system is blocked [21, 22].  
Figure 6: Schematic representation of the conversion of Gal-2 
dimer prodrug to galantamine monomer by esterase. 
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Figure 7: Schematic representation for NBD-abcavir dimer prodrug conversion to abcavir through the reduction of its disulfide bond. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another example is UDCA–AZT prodrug 8, designed by Dalpiaz et al. in which zidovudine (AZT) 9, was conjugated with 
Ursodeoxycholic Acid (UDCA), 10 and encapsulated in Poly (D, L-lactide-co-glicolide) (PLGA) nano-particulate system (Figure 8). Studies 
on UDCA–AZT have demonstrated three advantages to this technique: the ability of the prodrug to escape the active efflux transporter 
(AET) systems, controlling the release of the prodrug and enhancing the prodrug stability in physiologic fluids [23, 24].  
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Figure 8: Chemical structures of UDCA– AZT prodrug, 8, AZT, 9 and UDCA, 10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Passive diffusion, intracellular sequestration and trapping 
The sequestration mechanism has to be taken into 
consideration when evaluating drug transport across biological 
barriers. Trapping or sequestration of molecules in the 
intracellular space is one of the possible outcomes during the 
crossing biological barriers process. Intracellular space is over 
50% inhabited by membrane-bound compartments such as 
endosomes and lysosomes, and it has been shown that many 
amine-containing drugs can be sequestered in the acidic 
compartment of the intracellular space due to the presence of 
more positively charged molecules than neutral molecules in the 
lysosomes (pH = 4.5), compared to the cytoplasmic domain 
(neutral pH). Therefore, the positively charged molecules are 
trapped in the lysosomes without being efficiently permeated into 
the membranes. Consequently, amine drugs have the tendency to 
accumulate in the lysosomes, despite being transported via 
receptor-mediated endocytosis [1, 25].  
 
On the other hand, metabolism or transformation of 
certain drugs inside cells can be the cause of their trapping inside 
those cells. One of the common examples is Methotrexate (MTX) 
which enters into cells through transport receptors like 
membrane-associated folate binding protein (mFBP) and Reduced 
Folate receptor (RFC). After cellular uptake, MTX is converted 
into a highly negative charged polyglutamated MTX through 
polyglutamation of its glutamic acid. This results in molecules’ 
trapping inside the cells and hence an inhibition of their 
permeation [1, 26, 27]. 
There are a limited number of proposed solutions for 
overcoming the sequestration of drugs. One solution includes a 
derivatization of the drug’s amine group with a promoiety to 
provide a prodrug which is incapable to be protonated or 
positively charged, such that the prodrug molecule will not be 
protonated and sequestered when reached the lysosomes. 
However, this method is associated with a potential loss of the 
biological activity of the drug [1, 25, 28]. 
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Receptor-mediated transport 
Receptor-mediated transport mechanisms have been 
explored for the purpose of delivering small molecules, peptides, 
proteins, Nano particles and liposomes through biological 
barriers. Transporters found in biological barriers such as iron 
(i.e., transferrin receptor), RFC, mFBP, amino acid, di-/tri-
peptide, organic anions (e.g., OATP1A1, OATP1B3), organic 
cations (e.g., OCT1, OCTN2), Sodium-dependent Bile Acid 
(ASBT) family, sodium-dependent glucose (SGLT) family, 
Monocarboxylate (MCT) family and amino acid (PAT1) 
transporters have been exploited to carry drugs across biological 
barriers [1, 29, 30]. Among the intestinal transporters, Peptide 
Transporter 1 (PEPT1) has received the greatest attention for 
drugs transport due to its high prevalence throughout the entire 
small intestine, high capacity and varied substrate specificity. 
Moreover, both carriers PEPT1 and PEPT2 transport many β-
lactam antibiotics, valacyclovir and other drugs and prodrugs due 
to their steric resemblance to di- and tripeptides [1, 2, 6].  
Structure requirements for transport via PEPT1 
Indirect structure-affinity relationships have been relied 
on for the design of new substrates for PEPT1. The following 
factors are crucial for the determination of a drug affinity to 
PEPT1: molecular size, stereochemistry, peptide bond, N- and C- 
terminals, and side chains. Bailey et al. have built a template for 
PEPT1 substrates which consists of four key binding sites: (1) a 
strong binding site for N-terminal (NH3+), (2) hydrogen bonding 
to the carbonyl group of the first peptide bond, (3) a carboxylate 
binding site, and (4) a hydrophobic pocket for the amino acid side 
chain (Figure 9). Moreover, it has been shown that PEPT1 is 
stereo selective with preference and higher affinity to L-amino 
acids and is more inclined toward peptides containing bulky 
aliphatic side chains [4, 31-33].  
 
 
 
 
 
 
 
 
 
 
 
A combination of prodrug and receptor-mediated 
transport has been used to enhance the delivery of small drug 
molecules. For example, Zanamivir (Zan), 11, has poor 
physicochemical properties and consequently very low oral 
bioavailability (≈2%). A conjugation of Zan with L-valine (L- 
Val) to provide Zan-L-Val prodrug, 12 (Figure 10) was the 
strategy to solve the drug’s poor clinical profile. The conjugation 
was made via an ester-labile acyloxy promoiety and it was 
demonstrated that Zan-L-Val permeates into cells by using 
hPepT1 and as a result Zan bioavailability was enhanced [1, 2, 
34-37]. 
Figure 9: Substrate template with four key structural elements for 
binding to PepT1. 
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On the other hand, Glucose Transporter 1 (GLUT1) is 
the most important glucose transporter present at the surface of 
Brain Capillary Endothelial Cells (BCECs), and therefore, it is 
one of the potential candidates as a target for BBB targeting and 
delivering drugs to the brain. Therefore, and in an attempt to 
enhance the CNS analgesic properties of nonglycosylated 
compounds, several opioid analogs have been glycosylated and 
their delivery to the CNS was studied. For instance, Bonina et al 
have demonstrated that glycosylated L-dopa and dopamine 
derivatives are efficient prodrugs to target GLUT1 and to enhance 
their parent drug’s bioavailability [21, 38, 39]. 
Apical sodium dependent bile acid transporter (ASBT, 
SLC10A2)  
The human apical sodium dependent bile acid 
transporter (SLC10A2) is an essential carrier protein expressed in 
the small intestine. It is a member of Solute Carrier family (SLC) 
of transporters. Knowing the structure and disposition of the bile 
acids might facilitate a precise prodrug design that targets human 
apical sodium dependent Bile acid Transporter (hASBT) [40].  
Acyclovir valylchenodeoxycholate was designed to 
target hASBT.  It owns a favorable affinity for hASBT that is 
equivalent to that of the native bile acid; cholic acid. Studies have 
demonstrated a two-fold enhancement in acyclovir bioavailability 
from 25% to 48% in rats upon using acyclovir 
valylchenodeoxycholate. The explanation for the less than 
expected increase in acyclovir bioavailability is attributed to the 
hydrolysis of the prodrug in the stomach and proximal intestine.  
In addition, preliminary studies on drugs to be 
conjugated with bile acids showed that drugs can be attached to 
C-3 region of the steroidal ring through the C-24 carboxylate and 
C-17 region. However, results specified that C-24 conjugation 
boosts hASBT substrate affinity [40].  
Transferrin Receptors 
Transferrin Receptors (Tf-R) have been used in different 
aspects to deliver drugs through the BBB. More importantly, 
CRTIGPSVC-phages have been used as a new Tf-R-targeted 
technique which is composed of phage particles containing 
homing cyclic CRTIGPSVC peptides. These phage particles have 
the ability to use transferrin receptors indirectly to cross the BBB. 
For instance, apo-transferrin (apo-Tf) that imitates iron-bound 
transferrin Holo-Tf conformation is induced after the peptide on 
the phage interacts with apo-transferrin apo-Tf or iron-free Tf. 
Consequently, upon CRTIGPSVC peptide and transferrin 
binding, Transferrin Receptor (TfR) recognizes the phage-
peptide/Tf complex and transports the phage-peptide across the 
BBB. Experiments have revealed a 100-fold particle brain 
deposition after intravenous (IV) administration of CRTIGPSVC-
phages via the mouse tail vein compared to that of control phages 
without the peptide, demonstrating receptor-mediated transport. 
Based on this result it was concluded that CRTIGPSVC-phages 
are capable of delivering drugs to the brain. [1, 41, 42]. 
Sodium Dependent Multivitamin Transporter (SMVT) 
SMVT is primarily responsible for the uptake of 
vitamins such as biotin, pantothenic acid and lipoate in epithelial 
cells; therefore, it has been used for the delivery of poorly 
permeable drugs through conjugating a drug to biotin which 
serves as the recognizable moiety for the drug transport [43, 44]. 
The apparent affinity constant (Km) values of SMVT substrates 
are in the low micro molar range, leading to saturation of the 
transporter and thus, limiting the drug’s dose to be delivered via 
this carrier.  
To overcome this problem, Vadlapudi et al. have 
explored the possibility of using lipid-raft based drug conjugates 
to maximize the amount of a drug to be transported. The approach 
was to produce synergistic effect by combining both lipid and 
transporter/receptor targeted delivery. The lipid raft enhances the 
interaction of the prodrug with membrane transporters/receptors 
possibly by facilitating the docking of the targeted ligand into the 
binding domain of the transporter/receptor protein [44].  
Using this approach, different conjugates of Acyclovir 
(ACV) - biotinylated lipid prodrugs with various lipid rafts were 
synthesized and their ability to translocate across Caco-2 and 
MDCK-MDR1 cell lines by SMVT was assessed. Results 
demonstrated that the targeted lipid prodrugs of ACV have a 
higher affinity towards SMVT than ACV and their cellular 
accumulation is mainly mediated by SMVT as biotin uptake can 
be significantly inhibited [44].  
Prodrugs and Carrier Mediated Transport (CMT) 
CMT systems listed in Table 1 are responsible for 
transporting nutrients, vitamins and hormones into the central 
nervous system. They are highly stereospecific for their 
substrates, therefore, neuro active drugs are incapable of passing 
through these systems, which implies the use of the prodrug 
approach to overcome this obstacle [45]. 
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The following subsections illustrate some examples on the use of these systems to deliver drugs to the CNS. 
 
Table 1: CMT systems involved in the transport of nutrients into the CNS. 
Carrier Type Representative substrate Main expression in blood/ 
CNS barriers 
Neutral amino acid LAT 1 Phenylalanine BBB 
Hexose GLUT 1 Glucose BBB 
Monocarboxylic acid MCT 1 Lactic acid BBB 
Cationic amino acid CAT 1 Arginine BBB 
Nucleoside CNT 2 Adenosine BBB 
Ascorbic acid SVCT 2 Vitamin C Choroid Plexus 
 
 
Neutral amino acid (LAT1) 
LAT1 transporter is known to play a significant role in 
cell growth and proliferation; it is up regulated in malignant cells, 
which in turn has the potential to facilitate the intracellular 
accumulation of amino acid prodrugs in cancer cells.  
Alternatively, amino acid transporter targeted prodrug delivery 
might be a worthwhile strategy to be used to augment drug 
accumulation in P-gp overexpressing cells. This is based on a 
study which showed that P-gp mediated drug efflux could be 
circumvented by chemical modification of quinidine with neutral 
amino acids [46]. 
For instance, Patel et al. have conducted a study in 
which the possibility of overcoming P-gp mediated cellular efflux 
of quinidine was inspected via exploring the influence of 
modified neutral amino acids. L-isoleucine ester prodrug of 
quinidine (Ile-quinidine) was made and 14C-erythromycin was 
selected as a model substrate to study quinidine and Ile-quinidine 
interactions with P-gp. The results showed a significant 
improvement in the rate of 14C-erythromycin uptake in the 
presence of quinidine, whereas it remained fairly constant in the 
case of Ile- quinidine. Moreover, it was shown that quinidine has 
greater substrate affinity toward P-gp than Ile-quinidine and the 
latter was recognizable by multiple amino acid transporters such 
as LAT1, LAT2 and cationic amino acid transporter, as revealed 
from competitive inhibition studies [46, 47]. 
Prodrugs and the SVCT 2 system 
A class of Na+ dependent transporters named sodium-
vitamin C co-transporters (SVCT) is responsible for the intake of 
vitamin C (ascorbic acid, 13, Figure 11) in the body 
compartments of mammals. SVCT1 allows for the absorption of 
vitamin C from the intestine and its recovery by the kidneys, 
whereas SVCT2 is expressed by the retinal pigment epithelium 
and neuroepithelial cells of the choroid plexus and therefore it is 
responsible for the vitamin accumulation in the eyes and brain. 
Based on this, Pavan and coworkers have considered SVCT2 as a 
candidate for transporting neuroactive drugs into the CNS. For 
this purpose, they synthesized conjugates of vitamin C with 
neuroactive drugs and investigated their uptake to the CNS. The 
selected model compounds were nipecotic, kynurenic and 
diclophenamic acids, due to their inability to reach the brain from 
the bloodstream but still, they have the ability to induce 
therapeutic effect against various CNS pathologies. The 
conjugates of the selected compounds with vitamin C, 14-16, are 
shown in Figure 11. Human retinal pigment epithelium (HRPE) 
cells were chosen as the cell line because they selectively express 
the SVCT2 transporter. The study on compounds 14-16 revealed 
that nipecotic and kynurenic acids have the potential to interact 
with SVCT2 only as ascorbate conjugates, in which they behave 
as competitive inhibitors of vitamin C. Furthermore, the Br-
ascorbate, 17, conjugates; 18-20 (Figure 11) showed a similar 
behavior where nipecotic and kynurenic acids have the ability to 
interact with SVCT2 on the same binding site of vitamin C. On 
the other hand, diclofenamic acid behaved as a noncompetitive 
inhibitor. Based on these results the authors concluded that a 
conjugation with vitamin C induced further improvement of the 
drug affinity towards SVCT2 [45, 48-50]. 
 
Citation: Rafik Karaman (2015), Overview on the Recent Drugs Delivery Approaches. Aperito J Pharmacol Drug Design 2:114 
 
Volume 2 • Issue 1 • 114                                               www.aperito.org 
 
   
 
 
http://dx.doi.org/10.14437/2378-8968-2-114                                           Page 12 of 29 
 
Figure 11: Chemical structures of vitamin C, 13, its Br-ascorbate and their conjugates with nipecotic acid (Nipec), kynurenic acid (Kynur) 
and diclophenamic acid (14-20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue and tumor targeting 
Due to sever cytotoxic effects of most antitumor and 
antiviral agents, tissue selective drug delivery has been proposed. 
It has a significant potential to enhance the safety and efficacy 
profiles of drugs. For this purpose, different prodrug approaches 
have been investigated such as prodrugs activated by enzymes, 
preferentially localized in target tissues, specific transportation of 
prodrugs to the target tissues via specific transporters, and 
conjugates of drugs and molecules selectively bound to the target 
tissues [4, 51].  
 
 
 
 
 
 
Capecitabine is a triple prodrug of 5-fluorouracil (5-FU). 
It is rapidly and extensively absorbed and over 95% of its dose is 
recovered in urine after oral administration. Following oral 
absorption, capecitabine is converted in the liver to 5'-deoxy-5-
fluorocytidine (5’-dFCR) by the action of carboxylesterase, then 
to 5'-deoxy-5-fluoro-uridine (5’-dFUR) by the action of cytidine 
deaminase in the liver and tumor tissues, and finally to 5’-FU by 
the action of thymidine phosphorylase (dThdPase) in tumor cells 
(Figure 12). Capecitabine lessen the toxicity of the 
gastrointestinal tract that occurs with 5’-dFUR because it passes 
intact through gastrointestinal tract and is converted to 5’-FU in 
tumor tissues [4].  
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Figure 12: Three-step enzymatic conversion of capecitabine to 5-FU. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other methodologies involve an administration of an 
exogenous enzyme to reach the tumor site, followed by systemic 
administration of non-toxic prodrug that selectively converted 
into the active drug. The most common approaches are Antibody-
Directed Enzyme Prodrug Therapy (ADEPT), Gene-Directed 
Enzyme Prodrug Therapy (GDEPT) and Viral-Directed Enzyme 
Prodrug Therapy (VDEPT). ADEPT is a two-step approach in 
which an antibody- drug Activating Enzyme Conjugate (AEC) is 
given first and targeted to the tumor and accumulates 
predominantly at the tumor cells that have the desired tumor 
associated antigen, allowed to be localized and to clear the 
unbounded conjugate from the plasma, then, in the second step, a 
nontoxic prodrug is injected systemically and is converted to its 
corresponding active form by the localized enzyme. On the other 
hand, the concept in VDEPT and GDEPT approaches is based on 
packaging the gene encoding for the prodrug-activating 
exogenous enzyme either in a non-viral- (GDEPT) or viral- vector 
(VDEPT), which is then delivered to the tumor tissue where the 
target enzyme is expressed for selective transformation of 
prodrugs designed to be activated by this enzyme (Table 2) [52-
55].  
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Table 2: Examples of ADEPT, VDEPT and GDEPT in cancer therapy. 
 
1- Examples of ADEPT in Cancer Therapy 
Enzymes Antibodies Prodrugs Model systems 
Carboxy-peptidase G2 
 
Anti-CEA antibody CMDA Xenograft of human 
colon carcinoma 
Human β- glucuronidase 
 
Humanized CEA-specific 
binding region 
 
Anthracyclin 
prodrugs 
 
Murine L 1210 tumor cell 
Line 
Human β -glucuronidase 
 
Single-chain anti-CD20 
antibody 
 
Doxorubicin Fused protein 
2- Examples of VDEPT in Cancer Therapy 
Viral vectors Model  Enzymes delivered Prodrugs Model systems 
EBV  Nitroreductase (NTR) CB1954 EBV-positive B-cell lines 
Retrovirus  Yeast cytosine deaminase 5-FC Murine squamous 
carcinoma cells and 
YCD-expressing tumors 
Retrovirus Human CYP & P450 reductase  CPA & IFA Gliosarcoma cells and in 
vivo tumor model 
Adenovirus Human carboxylesterase  Irinotecan Human lung 
adenocarcinoma cell lines 
& nude mice tumor model 
3- Examples of GDEPT in Cancer Therapy 
Enzymes  Prodrugs Model systems 
Cytosine deaminase  
 
5-FC Murine fibroblast cells 
Thymidine kinase GCV Cisplatin-resistant human ovarian 
carcinoma cells 
Carboxypeptidase  MTX-alpha-peptide Cos-1 cells 
 
CEA, carcinoembryonic antigen; CMDA, 4-[(2-
chloroethyl)(2-mesyloxyethyl) amino] benzoyl-L-glutamic acid; 
5-FC, 5-fluorocytosine;GCV, ganciclovir; 5-FU, 5'-fluorouracil; 
5'-DFUR, 5'-deoxy-5-fluorouridine; MTX, methotrexate; 
CB1954, 5-(aziridin-1-yl)-2,4-dinitrobenzamide; CPA, 
cyclophosphamide; EBV, Epstein-Barr virus; IFA, ifosfamide; 
HSV, herpes simplex virus; NTR, nitroreductase. 
Targeting by prodrugs 
Brain targeted Chemical Delivery Systems (CDS) have 
been developed to deliver drugs to the CNS in a specific and 
sustained manner [45, 56]. This approach is based on chemical 
and/or enzymatic multistep conversion of the lipophilic prodrug 
moiety to its active drug. The mechanism of these CDS is based 
on a dihydropyridine pyridinium salt equilibrium type redox 
molecular carrier, similarly to the endogenous nicotinamide 
adenine dinucleotide (NADH/NAD+) coenzyme system. In this 
CDS, the lipophilic carrier, dihydropyridine, is attached to the 
drug for enhancing the drug’s BBB penetration before its 
conversion by enzymatic oxidation to a water soluble quaternary 
pyridinium salt. Upon intravenous (IV) administration, the 
dihydropyridine form is promptly distributed throughout the body 
as well as the CNS and is oxidized to impermeable pyridinium
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salt. The polar, oxidized prodrug (Drug-T+) is stocked behind the 
lipoidal BBB and remains locked-in in the CNS, whereas the 
ionic species formed peripherally are eliminated rapidly. The 
Drug-T+ conjugate remained in the CNS undergoes enzymatic 
hydrolysis that releases the active drug slowly and in a sustained 
manner, whereas the small carrier molecule, pyridinium salt, is 
actively transported out of the CNS [45]. Figures 13 and 14 
illustrate the application of this approach in delivering dopamine 
to the CNS. 
 
Figure 13: Drug delivery into CNS by molecular packaging and sequential metabolism. The drug is packaged by covalently attached 
lipophilic groups including a lipoidal Lpf and a 1, 4- dihydropyridine “Targetor” (T) that undergoes enzymatic oxidation and turns to a ionic, 
membrane-impermeable pyridinium moiety (T+). After distribution in the body and CNS by crossing the BBB, the CDS is converted to ionic 
compounds retained in the brain tissues, but ionic conjugates produced in the rest of the body are easily eliminated. The membrane 
impermeable conjugates “locked” into the brain undergo sequential metabolism and yield the drug in the CNS. A spacer (S) function controls 
the enzymatic rate of the drug’s release.  
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Figure 14: Regeneration of dopamine (22) from its amide-type of CDSs (21 and 23) in the CNS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perioli et al. have designed a prodrug backbone for non-
steroidal anti-inflammatory agents such as diclofenac, ibuprofen, 
ketoprofen, tiaprofenic acid and tolmetin to treat Alzheimer 
disease, in which the drug is attached to 1,4-dihydropyridine via 
an amino alcohol bridge and have studies their DBB penetration 
using the BBB VolSurf model developed by Crivori et al. The 
study revealed that among all tested compounds ibuprofen and 
diclofenac derivatives were the best candidates for BBB 
penetration, and the latter was found to correlate well with the log 
P of the tested prodrugs [5, 45, 57, 58].  
 
Another example of CDS approach which is considered 
as a challenging approach due to a rapid inactivation of peptides 
by ubiquitous peptidases has been successfully used to deliver 
enkephalin, thyrotropin-releasing hormone (TRH) and kyotorphin 
analogues to the brain. This successful delivery system 
overcomes three different delivery obstacles: (1) enhances passive 
transport by increasing the drug’s lipophilicity, (2) guarantees 
enzymatic stability to premature degradation and (3) uses the 
“lock-in” mechanism to provide targeting [45, 59, 60]. A 
demonstration of this system to deliver TRH is illustrated in 
Figure 15. 
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Figure 15: Chemical structure of TRH-CDS. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amino acid prodrugs for improved oral drug delivery 
Amino acids are considered as an excellent promoieties 
to increase the aqueous solubility of parent drugs. In addition, the 
salt forms of amino acid prodrugs increase the drug’s dissolution 
rate.  
Amino acid prodrugs have been utilized to improve oral 
bioavailability, sustained drug delivery, intravenous drug 
delivery, target drugs to their site of action and improve 
enzymatic stability [61]. 
Poor aqueous solubility is a common problem among 
therapeutics, thus, the prodrug approach was utilized to improve 
their aqueous solubility and hence it’s oral delivery. For instance,  
 
 
 
 
 
CAM-4562 is a selective nonpeptide neurokinin receptor 
antagonist (NK1). It is a dimethyl glycine ester of CAM-4451 and 
used as an antidepressant, antiemetic and anxiolytic agent.  
CAM-4451 has a poor oral bioavailability due to its very 
low aqueous solubility (<2 μg/ml). In an attempt to enhance its 
solubility, dimethyl glycine prodrug, CAM-4562 was synthesized. 
Studies on this prodrug demonstrated a 1500-fold greater 
solubility (3 mg/ml) and 3-fold better oral bioavailability (39%) 
than its parent drug. In addition, the study revealed a selective 
hydrolysis of dimethyl glycine prodrug to its parent drug by 
aminopeptidases, at the brush border membrane of the 
gastrointestinal tract [61, 62] (Figure 16). 
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Figure 16: Bioconversion of amino acid ester prodrug CAM-4562 to its parent drug, CAM-4451, by amino peptidases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another example of amino acid prodrugs is valacyclovir 
(Valtrex®).  It was the pioneer of L-valyl ester prodrugs, which 
achieved 3–5-times higher oral bioavailability (>60%) than its 
parent drug, acyclovir (10–20%) [61, 63]. 
Shortly after valacyclovir discovery, valganciclovir 
(Valcyte®) was designed. Similar to valcyclovir, valganciclovir is 
bioactivated by valacyclovirase and absorbed by the PepT1 and 
amino acid transporters (ATB0,+)  (Figure 17). Currently, there are 
several other L-valyl ester prodrugs, including nucleoside 
analogues levovirin valinate, valopicitabine, and valtorcitabine, 
that are under clinical investigation [61, 64]. 
 
 
 
 
 
 
 
Citation: Rafik Karaman (2015), Overview on the Recent Drugs Delivery Approaches. Aperito J Pharmacol Drug Design 2:114 
 
 
H
N
O
N
H
O
O
O
O
O
N
HN
H
N
O
N
H
O
O
O
OH
HN
CAM-4562
CAM-4451
Aminopeptidases
Volume 2 • Issue 1 • 114                                               www.aperito.org 
 
   
 
 
http://dx.doi.org/10.14437/2378-8968-2-114                                           Page 19 of 29 
 
Figure 17: Bioconversion of valganciclovir to its parent drug by valacyclovirase and to its corresponding triphosphates firstly by thymidine 
kinase and secondly by cellular kinases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, the amino acid prodrug approach was 
exploited for the improvement of metabolic stability of 
nucleoside drugs. For example, the potent and selective inhibitor 
of human cytomegalovirus (HCMV) 2-bromo-5,6-dichloro-1- (β-
D ribofuranosyl) benzimidazole (BDCRB)  has no clinical utility 
because of its rapid in vivo metabolism. The two enzymes, 8- 
 
 
oxoguanine DNA glycosylase (OGG1) and N-methyl purine 
DNA glycosylase (MPG), are responsible for the cleavage of the 
N-glycosidic bond of BCDRB, rendering the molecule inactive 
(Figure 18). Therefore, amino acid ester prodrugs of BDCRB (L-
Asp-BDCRB) were synthesized to enhance the metabolic 
stability, in vitro potency and systemic exposure of the drug [61, 
65]. 
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Figure 18: BDCRB N-glycosidic bond cleavage by 8-oxoguanine DNA glycosylase (OGG1) and N-methyl purine DNA glycosylase (MPG) 
and bio-evasion by enhanced stability via conversion to L-Asp-BDCRB prodrug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The use of computational approaches in modern prodrugs 
design 
Nowadays the use of computational methods by 
chemists and biochemists to compute energies, geometries and 
physicochemical properties for drug and prodrug molecules has 
received a great attention. Various quantum mechanics methods 
such as ab initio, semi-empirical and Density Functional Theory 
(DFT) and molecular mechanics are considered very useful tools 
that offer structure-energy calculations for the prediction of 
potential drugs and prodrugs alike [2]. 
The above mentioned modern computational methods 
have been utilized by us for the design of innovative prodrugs for 
commonly used drugs containing hydroxyl, phenol, or amine 
groups. For this purpose, we have computationally researched the 
mechanisms of a number of enzyme models that have been 
advocated to understand enzyme catalysis [66-87] and were 
exploited by us for the design of some novel prodrug promoieties 
[3, 88-110]. It is well known that the classic prodrug approach is 
focused on altering various physiochemical properties. On the 
other hand, the modern computational approach utilized by us, 
considers a design of linkers (promoieties) to be covalently linked 
to the active forms of drugs and upon reaching a physiologic 
environment (the target) undergo a programmed (controlled) 
intraconversion to non-toxic linker and the active parent drug 
without being activated by metabolic enzymes. Furthermore, 
since the promoieties of the prodrugs are small molecules, it is 
feasible that the prodrugs themselves will possess considerable 
therapeutic activity prior to their intra-conversion to the 
corresponding active parent drugs.  
Using, DFT, ab initio, semi-empirical and molecular 
mechanics methods, a number of enzyme models were 
investigated in an attempt to determine the factors affecting the 
rate-limiting step and exert a significant role in overriding the 
process rate. The enzyme models (intramolecular processes) that 
have been researched are: (1) proton transfer between two 
oxygens and proton transfer between nitrogen and
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oxygen in Kirby’s acetals [111-119] (2) acid-catalyzed hydrolysis 
in N-alkylmaleamic acids [111-119] (3) proton transfer between 
two oxygens in Menger’s rigid systems [120-124] (4) acid-
catalyzed lactonization of hydroxyl-acids as explored by Cohen 
and Menger [120-126] and (5) SN2-based catalyzed cyclization 
as studied by Beaumont Webster, Gardner, Dack, Bruice, Pandit, 
Karaman and Mandolini and Galli [127-131]. For the prodrug 
approach to be successful it is necessary that the prodrug 
undergoes inter- or intraconversion at the target site [127, 132]. 
The main problem in using the classical prodrug approach is the 
great difficulty in predicting the prodrug’s conversion rate, and 
thus the therapeutic profile of the administered prodrug [133, 
134] .  
On the other hand, using our approach utilizing 
intramolecularity (enzyme models) has a potential to provide an 
efficient chemical device to be used as a prodrug promoiety that 
can be linked to an active drug to yield a prodrug entity which can 
chemically, and not enzymatically, undergo cleavage to release 
the active parent drug in a controlled fashion. 
For instance, exploring the mechanism of Kirby’s acetals 
[111-119] led to a design of novel aza-nucleosides prodrugs to 
treat myelodysplastic syndromes [89]  and statins such as 
simvastatin and atorvastatin to reduce cholesterol levels in the 
blood circulation [88]. In these examples, the prodrug promoiety 
was directly attached to the hydroxyl group in the parent drug 
such that the prodrug will chemically cleave upon reaching the 
target such as stomach, intestine, and/or blood circulation, with 
rates that are solely determined by the chemical features of the 
therapeutically inactive promoiety (Kirby’s acetal). Further, acid-
catalyzed N-alkylmaleamic acids (Kirby’s enzyme model) [111-
118] was researched to be utilized as promoieties in the design of 
tranexamic acid prodrugs to treat bleeding conditions [84], 
acyclovir prodrugs as antiviral for the treatment of Herpes 
Simplex [135] and atovaquone prodrugs for the treatment of 
malaria [93, 136-138]. Menger’s intramolecular proton transfer in 
Kemp acid enzyme model [120-124] was also studied and 
exploited for the design of dopamine prodrugs to treat 
Parkinson’s disease [139]. Moreover, alkyl fumarates such as 
monomethyl and dimethyl fumarate prodrugs for the treatment of 
psoriasis were also designed and developed [95]. 
This novel prodrugs approach was also applied for the 
design of bitterless prodrugs for commonly used drugs having 
bitter sensation such as the pain killer agent, paracetamol, the 
anti-hypertensive drug atenolol, the decongestant agent, 
phenylephrine, the anti-inflammatory drugs, diclofenac and 
mefenamic acid and the antibacterials cefuroxime, amoxicillin 
and cephalexin [91, 96-98, 101-104]. The role of the linker in the 
above mentioned prodrugs is to block the amine (for the 
antibacterial agents) or hydroxyl groups (in paracetamol, atenolol 
and etc.) which are believed to be responsible for the drug bitter 
taste of the parent drug. The only chemical difference between the 
designed antibacterials prodrugs and their parent drugs is that the 
free amine group in the parent drug is replaced with an amide 
group (Figure 19). Replacing the amine with an amide group 
eliminates the capability of the antibacterial to interact with the 
bitter taste receptor, thus masking the bitter sensation of the 
parent antibacterial drug.  
Figure 19: Chemical structures of amoxicillin and cephalexin and their prodrugs, amoxicillin ProD 1 and cephalexin ProD 1, respectively. 
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Peptides 
Peptides have received a great attention as drug 
candidates due to their significant importance to efficiently and 
specifically cure many CNS diseases. Various studies have 
demonstrated that peptides penetration into the brain cannot be 
simply predicted by single molecular properties or net charges. 
Therefore, more comprehensive models were proposed in order to 
evaluate possible BBB permeability of peptides. For instance, 
Giralt and coworkers were able to construct a Genetic Algorithm 
(GA)-based model where nine physiochemical parameters 
including log P, conformation and aromaticity were considered to 
model the penetration of BBB by randomly generated peptides. 
From this study it was concluded that BBB permeability is 
difficult to be predicted using simple rules of small molecules and 
it requires combined approaches. Recently, the light has been 
spotted on a family of short peptides known as Cell Penetration 
Peptides (CPPs) as potential peptide-based delivery vectors. 
Some efforts were made to predict sequences that have the 
potential to penetrate into biological barriers, especially BBB.  
Recently a set of descriptors called Z-scaled was used to model 
the BBB permeability. It derived from a lot of physiochemical 
parameters for each amino acid. The study revealed that bulk 
property values (z∑/n) have a good predictive ability. The 
shortcoming of these descriptors is overlooking the peptides 
sequence because values of z∑/n are similar for a set of scrambles 
analogues. [5, 140, 141].  
Paracellular pathways 
Paracellular pathways of the intestinal mucosa and BBB 
share some similarities. Via this pathway, small hydrophilic 
molecules and ions can passively pierce, whereas large molecules 
can’t pass due to the presence of tight junctions. Moreover, 
peptides and proteins can’t effectively pass through these 
pathways, thus making it difficult for their delivery to the brain or 
for oral absorption. Modulation of the intercellular junctions to 
increase their porosity and permit the passage of large hydrophilic 
molecules (of certain size to prevent toxins entrance) was one of 
the experienced techniques to improve the delivery of large 
hydrophilic molecules. Beforehand, a success in opening the 
intercellular junctions of the BBB to deliver anticancer drugs to 
patients with brain tumors has been reached using a hypertonic 
solution of mannitol )[1, 142-144].  
Nano particles to improve drug delivery across biological 
barriers 
Nano particles were among the strategies investigated to 
improve delivery of drugs across the intestinal mucosa and the 
BBB. It has been demonstrated that Nano particles with peptide 
ligands are able to pass the intestinal mucosa using receptor-
mediated transport. Therefore, Receptor-Mediated Transcytosis 
(RMT) was used for efficacious delivery of Nano particles 
through the intestinal mucosa and BBB. Particles decorated with 
large molecules such as apolipoprotein, ligands to Transferrin 
(Tf) receptors (i.e., Tf and anti-Tf-receptor antibodies), and 
antibodies to insulin receptors were used and achieved a 
successful delivery of Nano particles across BBB [1, 145, 146]. 
Despite the fact that Nano particles can be internalized 
via pinocytosis or absorptive-mediated transcytosis (AMP), these 
processes are not efficient due to the low amount of transported 
Nano particles. Besides, Nano particles can be taken up by other 
cells non-selectively in the case of absence of targeting molecules 
[1, 145]. 
On the other hand, Nano particles do not have the ability 
to cross via the paracellular pathway because of their size. Small 
particles (<200 nm) pass via clathrin-mediated endocytosis and 
large particles (500 nm) via caveolae-mediated endocytosis. Yet, 
endocytosis is accompanied with its shortcomings that were 
mentioned previously. The most promising particles for 
delivering anticancer agents through BBB to treat brain tumors 
are modified liposomes [1, 145, 147]. 
Summary and Conclusion 
Delivery of therapeutics to their target sites is considered 
crucially important to the drug discovery and development sector. 
Various approaches and tarnishes have been invoked and used in 
order to improve the delivery of a variety of drugs. Among the 
utilized methods is the use of the natural occurring transporters to 
enhance the passive diffusion of drugs through transcellular 
pathways and to modify efflux pumps to avoid P-gp activity. 
Nucleoside analogues were exploited to improve drug’s delivery 
and CYP-activated prodrugs, called HepDirect, were utilized to 
target drugs to the liver, in which they remain inactive until being 
activated by specific enzymes in the liver. 
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Moreover, receptor-mediated transport mechanisms have 
been explored for the purpose of delivering small molecules, 
peptides, proteins, nanoparticles and liposomes through biological 
barriers. These include PEPT1, GLUT1, hASBT and Transferrin 
Receptors (Tf-R). In addition, Carrier Mediated Transport (CMT) 
systems such as neutral amino acid (LAT1), hexose (GLUT1), 
monocarboxylic acid (MCT 1), Cationic Amino Acid (CAT 1), 
nucleoside (CNT 2) and ascorbic acid (SVCT 2) were heavily 
studied. 
As for cancer drugs, tissue selective drug delivery is the 
most exploited approach in which prodrugs are activated by 
enzymes preferentially localized in target tissues, and specific 
transportation of prodrugs to the target tissues is accomplished via 
specific transporters, conjugates of drugs and molecules 
selectively bound to the target tissues. Other methods which were 
investigated to deliver anti-cancer drugs include ADEPT, GDEPT 
and VDEPT.  
Likewise, enzymes involve in the bioconversion of ester-
based prodrugs were also used for the activation (hydrolysis) of 
prodrugs to their corresponding active therapeutic agents.  
Amino acid prodrugs have been investigated to improve 
drug delivery and other associated drugs’ pharmaceutical issues.   
The combined results emerged from the studies described in this 
review emphasize the importance of the prodrug approach and the 
use of transporters in enhancing drug delivery and overcoming 
obstacles stem from physiological barriers or pharmaceutical 
issues. 
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